Overview
TNGX market data
Price History
TNGX price chart · 1M
- O
- 24.67
- H
- 26.83
- L
- 24.38
- C
- 26.11
- Vol
- 148,968.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $24.67
- Previous Close
- $24.76
- Day High
- $26.83
- Day Low
- $24.38
- 52 Week High
- $34.35
- 52 Week Low
- $16.12
- 7 Day Return
- +3.57%
- 30 Day Return
- -2.36%
- 90 Day Return
- +30.62%
- 1 Year Return
- +54.04%
- Daily Notional Volume
- $3.9M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.87 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.17 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -151.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.25 – $34.39 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.3B · P/B 1.67 · P/S 65.17.
Company News
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68Benzinga · Aug 18, 2026, 11:25 AM
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35Benzinga · Aug 12, 2026, 12:24 PM
Tango Therapeutics Files Prospectus For Up To $400M Common Stock OfferingBenzinga · Aug 11, 2026, 9:14 PM
8-K filing — Tango Therapeutics, Inc. (TNGX)SEC EDGAR · Aug 11, 2026, 9:13 PM
Tango Therapeutics Q2 EPS $(0.37) Misses $(0.32) EstimateBenzinga · Aug 11, 2026, 11:27 AM
8-K/A filing — Tango Therapeutics, Inc. (TNGX)SEC EDGAR · Aug 7, 2026, 10:41 AM
Reported Earlier, Tango Therapeutics Announces Executive Chairman Dr. Barbara Weber To Step Down From Board Role To Pursue Other VenturesBenzinga · Aug 7, 2026, 8:00 AM
Tango Therapeutics Announces Executive Chair TransitionGlobenewswire Inc · Aug 6, 2026, 11:15 PM
Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40Benzinga · Jul 17, 2026, 6:59 PM
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayBenzinga · Jul 15, 2026, 10:59 AM